79 related articles for article (PubMed ID: 12660131)
1. [Gene expression profiling of multiple myeloma].
Minvielle S
Bull Cancer; 2003 Feb; 90(2):127-30. PubMed ID: 12660131
[TBL] [Abstract][Full Text] [Related]
2. miRNAs in multiple myeloma--a survival relevant complex regulator of gene expression.
Seckinger A; Meißner T; Moreaux J; Benes V; Hillengass J; Castoldi M; Zimmermann J; Ho AD; Jauch A; Goldschmidt H; Klein B; Hose D
Oncotarget; 2015 Nov; 6(36):39165-83. PubMed ID: 26472281
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
[TBL] [Abstract][Full Text] [Related]
4. Multiple myeloma.
Sirohi B; Powles R
Lancet; 2004 Mar; 363(9412):875-87. PubMed ID: 15031034
[TBL] [Abstract][Full Text] [Related]
5. SAGE analysis highlights the importance of p53csv, ddx5, mapkapk2 and ranbp2 to multiple myeloma tumorigenesis.
Felix RS; Colleoni GW; Caballero OL; Yamamoto M; Almeida MS; Andrade VC; Chauffaille Mde L; Silva WA; Begnami MD; Soares FA; Simpson AJ; Zago MA; Vettore AL
Cancer Lett; 2009 Jun; 278(1):41-8. PubMed ID: 19171422
[TBL] [Abstract][Full Text] [Related]
6. Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma.
Nojima M; Maruyama R; Yasui H; Suzuki H; Maruyama Y; Tarasawa I; Sasaki Y; Asaoku H; Sakai H; Hayashi T; Mori M; Imai K; Tokino T; Ishida T; Toyota M; Shinomura Y
Clin Cancer Res; 2009 Jul; 15(13):4356-64. PubMed ID: 19549772
[TBL] [Abstract][Full Text] [Related]
7. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling.
Chng WJ; Kumar S; Vanwier S; Ahmann G; Price-Troska T; Henderson K; Chung TH; Kim S; Mulligan G; Bryant B; Carpten J; Gertz M; Rajkumar SV; Lacy M; Dispenzieri A; Kyle R; Greipp P; Bergsagel PL; Fonseca R
Cancer Res; 2007 Apr; 67(7):2982-9. PubMed ID: 17409404
[TBL] [Abstract][Full Text] [Related]
8. Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays.
De Vos J; Thykjaer T; Tarte K; Ensslen M; Raynaud P; Requirand G; Pellet F; Pantesco V; Rème T; Jourdan M; Rossi JF; Ørntoft T; Klein B
Oncogene; 2002 Oct; 21(44):6848-57. PubMed ID: 12360412
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling in multiple myeloma--reporting of entities, risk, and targets in clinical routine.
Meissner T; Seckinger A; Rème T; Hielscher T; Möhler T; Neben K; Goldschmidt H; Klein B; Hose D
Clin Cancer Res; 2011 Dec; 17(23):7240-7. PubMed ID: 21986844
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma.
Mattioli M; Agnelli L; Fabris S; Baldini L; Morabito F; Bicciato S; Verdelli D; Intini D; Nobili L; Cro L; Pruneri G; Callea V; Stelitano C; Maiolo AT; Lombardi L; Neri A
Oncogene; 2005 Apr; 24(15):2461-73. PubMed ID: 15735737
[TBL] [Abstract][Full Text] [Related]
11. Insights from the gene expression profiling of multiple myeloma.
Claudio JO; Masih-Khan E; Stewart AK
Curr Hematol Rep; 2004 Jan; 3(1):67-73. PubMed ID: 14695854
[TBL] [Abstract][Full Text] [Related]
12. Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein.
van de Donk NW; Kamphuis MM; van Dijk M; Borst HP; Bloem AC; Lokhorst HM
Leukemia; 2003 Jan; 17(1):211-9. PubMed ID: 12529680
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiling defines a high-risk entity of multiple myeloma.
Zhan FH; Barlogie B; John D S
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Apr; 32(2):191-203. PubMed ID: 17478923
[TBL] [Abstract][Full Text] [Related]
14. Expression and function of toll-like receptors in multiple myeloma patients: toll-like receptor ligands promote multiple myeloma cell growth and survival via activation of nuclear factor-kappaB.
Xu Y; Zhao Y; Huang H; Chen G; Wu X; Wang Y; Chang W; Zhu Z; Feng Y; Wu D
Br J Haematol; 2010 Sep; 150(5):543-53. PubMed ID: 20629663
[TBL] [Abstract][Full Text] [Related]
15. Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway.
Zhang J; Choi Y; Mavromatis B; Lichtenstein A; Li W
Oncogene; 2003 Sep; 22(40):6289-95. PubMed ID: 13679867
[TBL] [Abstract][Full Text] [Related]
16. Multiple myeloma.
Harousseau JL; Shaughnessy J; Richardson P
Hematology Am Soc Hematol Educ Program; 2004; ():237-56. PubMed ID: 15561686
[TBL] [Abstract][Full Text] [Related]
17. Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells.
Fagerli UM; Ullrich K; Stühmer T; Holien T; Köchert K; Holt RU; Bruland O; Chatterjee M; Nogai H; Lenz G; Shaughnessy JD; Mathas S; Sundan A; Bargou RC; Dörken B; Børset M; Janz M
Oncogene; 2011 Jul; 30(28):3198-206. PubMed ID: 21478911
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profiling and multiple myeloma.
Shaughnessy J; Zhan F; Barlogie B; Stewart AK
Best Pract Res Clin Haematol; 2005; 18(4):537-52. PubMed ID: 16026736
[TBL] [Abstract][Full Text] [Related]
19. Advances in biology and therapy of multiple myeloma.
Barillé-Nion S; Barlogie B; Bataille R; Bergsagel PL; Epstein J; Fenton RG; Jacobson J; Kuehl WM; Shaughnessy J; Tricot G
Hematology Am Soc Hematol Educ Program; 2003; ():248-78. PubMed ID: 14633785
[TBL] [Abstract][Full Text] [Related]
20. Raloxifene-induced myeloma cell apoptosis: a study of nuclear factor-kappaB inhibition and gene expression signature.
Olivier S; Close P; Castermans E; de Leval L; Tabruyn S; Chariot A; Malaise M; Merville MP; Bours V; Franchimont N
Mol Pharmacol; 2006 May; 69(5):1615-23. PubMed ID: 16497877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
